Livagen

Bioregulators Research compound (not approved for human use)

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) · also known as KEDA, Lys-Glu-Asp-Ala

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Livagen is mainly known from chromatin studies in lymphocytes from older people. It is a short bioregulator with a small literature from one research group, and no human trial defines a vial-based dose.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	500 mcg	0.075 mL	7.5
Standard	1 mg	0.15 mL	15
Higher	2 mg	0.3 mL	30

Frequency: Once daily, subcutaneous (8-12 week courses, community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

In cell studies it was reported to loosen condensed chromatin and activate ribosomal genes in lymphocytes from older donors; the relevance to liver tissue or whole-body effects is not established.

Researched for

Studied in lymphocytes from older people for chromatin decondensation and ribosomal gene activity.
Examined in a study comparing a polypeptide liver complex with the KEDA tetrapeptide.
Examined for effects on aging-related chromosome features in cultured human cells.

Notes

Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.

Sources

Last reviewed 2026-10-06.

Vesugen

Synthetic tripeptide bioregulator (Lys-Glu-Asp)

Vesugen is a three-residue peptide (lysine, glutamate, aspartate) from the Khavinson family, associated with blood vessels and the cardiovascular system.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

Testagen

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly)

Testagen is a four-residue peptide (lysine, glutamate, aspartate, glycine) modeled on pituitary extracts, linked in the Khavinson literature to the pituitary-gonadal axis.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)